

Special Issue

Research on Biomarkers for Cardiometabolic Risk in Metabolic Syndrome

Message from the Guest Editors

A comprehensive approach that influences the main components of Metabolic syndrome is essential, especially in high-risk patients, to normalize the primary metabolic abnormalities, which will reduce the cardiovascular risk and the risk of DM2 in the long term. Recently, more and more attention has been directed to personalized medicine and an individualized approach not only in relation to therapeutic but also to preventive interventions aimed at influencing risk factors and reducing long-term complications. The personalized approach is based on the individual characteristics of individual patients, including different biomarkers and genetic variants. This Special Issue aims to collect research articles and review exploring biomarkers associated with cardiometabolic risk in individuals with metabolic syndrome, with a focus on identifying novel markers and elucidating their role in disease pathogenesis and prevention.

Guest Editors

Dr. Antoaneta Trifonova Gateva


Department of Internal Medicine, Medical Faculty, Medical University Sofia, Sofia, Bulgaria

Dr. Yavor Sashov Assyov

Department of Internal Medicine, Medical Faculty, Medical University Sofia, Sofia, Bulgaria

Deadline for manuscript submissions

4 August 2025



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/203015

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).